Entera Bio to present EB613 Phase 3 study design at ASBMR meeting
Tweet Send to a Friend
Entera Bio Ltd. (NASDAQ: ENTX) announced that a presentation of the clinical study design for its planned Phase 3 trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




